Arterial Infusion of Combination Therapy Using Dibutyryl Adenosine 3',5' -Monophosphate and Mitomycin C for Hepatocellular Carcinoma Occluding Main Portal Vein: Case Studies

Abstract

Intraarterial infusion therapy combining dibutyryl adenosine 3',5' monophosphate and mitomycin C was administered to 8 patients with hepato cellular carcinoma occluding the main portal vein. Three patients survived more than nine months, including 1 who has been well for forty-eight months with technical imaging showing complete regression. A decreased level of serum α-fetoprotein of more than 90% was obtained in 38% of patients. Causes of death included hepatic failure, rupture of esophageal varices, acute gastric ul cer, and cerebral hemorrhage. It is concluded that the combination therapy may be useful for HCC.